123 related articles for article (PubMed ID: 15014015)
21. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Friedman HS; Pluda J; Quinn JA; Ewesuedo RB; Long L; Friedman AH; Cokgor I; Colvin OM; Haglund MM; Ashley DM; Rich JN; Sampson J; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Stewart ES; Tourt-Uhlig S; Garcia-Turner AM; Herndon JE; Bigner DD; Dolan ME
J Clin Oncol; 2000 Oct; 18(20):3522-8. PubMed ID: 11032594
[TBL] [Abstract][Full Text] [Related]
22. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.
Awada A; Gil T; Sales F; Dubuisson M; Vereecken P; Klastersky J; Moerman C; de Valeriola D; Piccart MJ
Anticancer Drugs; 2004 Jun; 15(5):499-502. PubMed ID: 15166625
[TBL] [Abstract][Full Text] [Related]
23. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Wedge SR; Porteous JK; Newlands ES
Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
Friedman HS; Dolan ME; Moschel RC; Pegg AE; Felker GM; Rich J; Bigner DD; Schold SC
J Natl Cancer Inst; 1992 Dec; 84(24):1926-31. PubMed ID: 1334154
[TBL] [Abstract][Full Text] [Related]
26. A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Garrison MA; Hammond LA; Geyer CE; Schwartz G; Tolcher AW; Smetzer L; Figueroa JA; Ducharme M; Coyle J; Takimoto CH; De Jager RL; Rowinsky EK
Clin Cancer Res; 2003 Jul; 9(7):2527-37. PubMed ID: 12855627
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE
Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
[TBL] [Abstract][Full Text] [Related]
29. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
30. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
Schwartz GH; Patnaik A; Hammond LA; Rizzo J; Berg K; Von Hoff DD; Rowinsky EK
Ann Oncol; 2003 May; 14(5):775-82. PubMed ID: 12702533
[TBL] [Abstract][Full Text] [Related]
32. Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
Geoerger B; Vassal G; Doz F; O'Quigley J; Wartelle M; Watson AJ; Raquin MA; Frappaz D; Chastagner P; Gentet JC; Rubie H; Couanet D; Geoffray A; Djafari L; Margison GP; Pein F
Br J Cancer; 2005 Sep; 93(5):529-37. PubMed ID: 16136028
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Rangwala R; Leone R; Chang YC; Fecher LA; Schuchter LM; Kramer A; Tan KS; Heitjan DF; Rodgers G; Gallagher M; Piao S; Troxel AB; Evans TL; DeMichele AM; Nathanson KL; O'Dwyer PJ; Kaiser J; Pontiggia L; Davis LE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1369-79. PubMed ID: 24991839
[TBL] [Abstract][Full Text] [Related]
34. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M; Middleton MR; Bridgewater J; Lee SM; Dawson M; Jowle D; Halbert G; Waller S; McGrath H; Gumbrell L; McElhinney RS; Donnelly D; McMurry TB; Margison GP
Clin Cancer Res; 2006 Mar; 12(5):1577-84. PubMed ID: 16533784
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
36. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
Vera K; Djafari L; Faivre S; Guillamo JS; Djazouli K; Osorio M; Parker F; Cioloca C; Abdulkarim B; Armand JP; Raymond E
Ann Oncol; 2004 Jan; 15(1):161-71. PubMed ID: 14679137
[TBL] [Abstract][Full Text] [Related]
37. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
[TBL] [Abstract][Full Text] [Related]
38. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Quinn JA; Pluda J; Dolan ME; Delaney S; Kaplan R; Rich JN; Friedman AH; Reardon DA; Sampson JH; Colvin OM; Haglund MM; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Gururangan S; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
J Clin Oncol; 2002 May; 20(9):2277-83. PubMed ID: 11980998
[TBL] [Abstract][Full Text] [Related]
40. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Schilsky RL; Dolan ME; Bertucci D; Ewesuedo RB; Vogelzang NJ; Mani S; Wilson LR; Ratain MJ
Clin Cancer Res; 2000 Aug; 6(8):3025-31. PubMed ID: 10955780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
